Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Baoyuan, Zhang, Yan, Zhang, Jiangwei, Liu, Ping, Jiao, Bo, Wang, Zaiqi, Ren, Ruibao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373085/
https://www.ncbi.nlm.nih.gov/pubmed/34151545
http://dx.doi.org/10.1002/advs.202100250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373085/
https://www.ncbi.nlm.nih.gov/pubmed/34151545
http://dx.doi.org/10.1002/advs.202100250

Ejemplares similares